Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by Chemdogon Jun 20, 2017 9:09pm

79 Views

Post# 26385437

RE:Chart is setting up nicely here for a reversal + run

hey GreenNme
I agree 100% with you on the share price recovery..we just have to be patient..
GLTA

GreenNme wrote: The doji on Thursday, the big bull volume and %20 day on Friday, a healthy pullback yesterday and the inverted hammer on low volume today tells me sellers are drying up. My prediction is that we see some momentum to the upside the remainder of the week and a close at 18.5 cents on Friday. I think once this breaks above 20 cents it can bounce back to 25-30 cents fairly quickly. If Aphria sees value in Kaly at 45 cents, buying the same shares at one third the price seems like a very good play to me.

Bullboard Posts

How a junior advances one of the largest undeveloped diamond projects